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Background. New drug use patterns may increase the risk of human immunodeficiency virus and hepatitis infections. In France,
new injection patterns among youths with diverse social backgrounds have emerged, which may explain the persistently high rates
of hepatitis C virus infection. This study explores factors associated with injection risk behaviours at first injection among users
who began injecting in the post-2000 era. Methods. A cross-sectional study was conducted on the Internet from October 2010
to March 2011, through an online questionnaire. Multivariate logistic regression identified the independent correlates of needle
sharing and equipment (cooker/cotton filter) sharing. Results. Among the 262 respondents (mean age 25 years), 65% were male.
Both risk behaviours were positively associated with initiation before 18 years of age (aOR 3.7 CI 95% 1.3–10.6 and aOR 3.0 CI 95%
1.3–7.0) and being injected by another person (aOR 3.1 CI 95% 1.0–9.9 and aOR 3.0 CI 95% 1.3–7.1). Initiation at a party was an
independent correlate of equipment sharing (aOR 2.6 95% CI 1.0–6.8). Conclusions. Results suggest a need for innovative harm
reduction programmes targeting a variety of settings and populations, including youths and diverse party scenes. Education of
current injectors to protect both themselves and those they might initiate into injection is critically important.
1. Introduction
Injection drug use has long been regarded as a serious public
health issue worldwide. According to a systematic review of
the epidemiology of hepatitis B and hepatitis C, approxi-
mately 10 million intravenous drug users (IDUs) worldwide
are carriers of anti-hepatitis C virus (HCV) antibodies, and
1.2 million IDUs carry HbsAg antibodies [1]. Additionally,
approximately 19% ofmillion people who inject drugsmay be
human immunodeficiency virus- (HIV-) positive [2]. How-
ever, the proportion of cases related to drug use varies widely
across countries depending on implementation of harm
reduction policies, law enforcement practices and drug use
practices, and their changes over time. In France, new diag-
noses of HIV infection among drug users have dramatically
decreased and, in recent years, have accounted for 2%-3% of
total cases, which amounts to approximately 70 cases per year
[3]. In this population, prevalence decreased from 20% in the
early 1990s to 10% in 2011 [4]. These changes followed the
introduction of free access to syringes in pharmacies (1987),
the implementation of syringe exchange programmes, low-
threshold services (1990), and opiate substitution treatments
(1995). However, HCV infection prevalence has decreased
more modestly, from 60% in the early 2000s to 44% in 2011
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(8-9% among those under 30 years of age) [4]. Transmission
of HIV and HCV remains a matter of concern with the use
of a growing variety of drugs and injection practices and
current evidence about sharing practices and HCV serocon-
version [5], especially in the context of the growing nightlife
culture among youths with very diverse social backgrounds
[6, 7].
Similarly to otherwestern European countries, France has
a longstanding tradition of injection drug use, mainly heroin
injection [8]. In 2006, approximately 145,000 individuals in
France were estimated to have used the intravenous route
of administration at least once in their lifetime [9]. After a
period of injection drug use decline in France in the early
2000s, recent data suggest a levelling-off of injection practices
since 2008, with the overall level remaining high [10, 11],
especially among the youngest users [4].
A recent European report [12] shows an upward trend
in the prevalence of high-risk drug users between 2006 and
2011 in France. These results are close to the European Union
average. Furthermore, ethnographic research [13] has shown
the emergence of new groups of IDUs and new patterns of
substance abuse. Aside from underprivileged youths, new
consumers belonging to diverse social backgrounds, such as
users at raves/dance parties, use a wide spectrum of sub-
stances (hallucinogens, amphetamines, synthetic products,
and cocaine and its derivatives), as observed by surveillance
monitoring of emerging drug use trends [14, 15]. Heroin
and other opiates, including prescription opioids (morphine-
sulphate and buprenorphine), are used occasionally, some-
times with other substances, for their relaxing effects. Injec-
tion is one aspect of this behaviour [16–18]. Therefore, the
current harm reduction strategies, developed at a time when
heroin injectionwas predominant, especially among injectors
of low socioeconomic backgrounds, may not be reaching
these new initiates to injection; these users are at high risk of
exposure to HCV/HIV, which is often acquired shortly after
initiation into injection [19–25].
The course of the first injection, including the circum-
stances and the people involved, has been shown to be
particularly significant with respect to the future injection
practices of new injectors [26]. Initiates are generally poorly
informed regarding the techniques and risks of injection.
Thus, the majority are injected or helped by experienced
injectors [18, 27–33]. A recent modelling study carried out in
Scotland estimated that each injector initiates approximately
0.26 individuals into injection each year [34]. Initiates are
particularly vulnerable at the time of first injection because
most are at the mercy of events. To date, most studies on
initiation into injection drug use have been carried out among
marginalised individuals who were mainly recruited through
drug dependence clinics or injection drug user networks [18,
26–31, 33, 35–39]. In France, two epidemiological studieswere
carried out addressing the first injection in this population
[30, 31]; however, none has focussed on recent initiations that
took place in an era marked by changes in drug use patterns
and drug-using environments.
To document the profile of new initiates, the PrimInject
study was carried out using the Internet to reach current or
former injectors and obtain descriptions of circumstances,
behaviours, and potential exposure to blood-borne infections
at the time of injection initiation. Launched within the
context of changing trends in substance use, drug policy,
and drug supply, PrimInject was the first study to describe
new injectors and the circumstances surrounding their first
injections over time [40].The aim of this exploratory analysis
is to examine injection risk behaviours and correlates at the
time of initiation into injection drug use among individuals
who began injection in the post-2000 era in France.
2. Methods
2.1. Population and Design. PrimInject used the Internet to
reach young and diverse population, including individuals
who had injected drugs only a few times and those who
had engaged in long-term injection drug use. The electronic
music scene was particularly targeted for these reasons [18,
41]. Indeed, the Internet is one of the main communication
channels for participants in the electronic music scene. It
is also effective in reaching small and hidden populations
[42, 43]. Promotional banners using visual codes associated
with the party scene invited potential participants to share
their experiences with drug injection. PrimInject was also
promoted in a wide range of harm reduction programmes
and services in which the Internet was made accessible to
reach drug users using low-threshold services and self-help
groups. A short questionnaire was developed and pretested
among drug users. Data collection took place from October
2010 to March 2011. The detailed methodology has been
described elsewhere [40] and in an online methodological
appendix (see Supplementary Materials available online at
http://dx.doi.org/10.1155/2015/507214).
2.2. Questionnaire and Variables of Interest. The question-
naire covered current social status (e.g., education and
employment), history of legal and illegal substance use, and
the detailed circumstances surrounding the first injection. To
avoid missing data, an answer was required for each question
(blank responses were not allowed).
The outcomes of interest were two injection risk behav-
iours: (1) receptive needle sharing, defined as injection with a
syringe previously used by another person at first injection,
and (2) receptive sharing of other injection equipment,
defined as using a cooker or cotton filter previously used by
another individual.
The data on correlates pertained to several domains.
One concerned participants’ history of substance use before
injection (use and age at first use of cannabis, ecstasy, co-
caine, amphetamines, methamphetamine, ketamine, heroin,
buprenorphine, methadone, other opiates, and/or hallucino-
gens), including heavy alcohol use (drunkenness). Early use
for each substance was defined as use at 14 years of age or
younger [44]. Age at first injection was also assessed and
dichotomized (<18 years old and ≥18 years old).
The circumstances of first injection were documented,
including age at that time, the type of substances used,
year, and location (home or another private place, squat,
street, outdoor location, or van/car), whether the injection
took place during a party (whether in a public or private
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Baseline questionnaire
Completed questionnaire (at least 
partially)
Eligible for analysis (1) Individuals who never injected (35%, n = 455) 
(3) First injection section or date of first injection 
(4) Not living in France (3%, n = 40)
(5) Individuals who reported injecting drugs
Early dropout (before Q2) 
(N = 1,884)
(20%, N = 262)
(30%, n = 566)
(n = 1,318)
Excluded from analysis (80%, n = 1056)
(2) Inconsistent responses (3%, n = 42)
being incomplete (25%, n = 332)
before 2000 (14%, n = 187)
Figure 1: Flow chart of data cleaning and exclusion criteria from the analysis.
context and whether outdoors or indoors), whether the
participant was alone, whether the participant injected him-
or herself or was assisted, whether the first injection was
planned, and whether the drug had been bought or given.
The history of injection from initiation to the time of data
collection was documented with two variables: the lifetime
number of injections (only once, 2–10 times, 11 times, or
more) and injection during the previous month (yes/no).
Finally, the year of initiation was estimated by subtracting
the age at the time of initiation from the age at the time of
the interview. Subjects who injected earlier than 2000 were
excluded from the present analysis to focus on themost recent
injectors.
2.3. Data Analysis. Descriptive statistics were used to char-
acterize the study sample included frequency distributions
for categorical variables. To examine the association between
the correlates and each outcome, univariate and multivariate
logistic regression analyses were conducted. All the variables
with a 𝑝 value < 0.25 for one of the outcomes in univariate
analyses, according to the Wald test, were considered for
inclusion in the multivariate models. Early use of substances
was not included in the multivariate logistic regressions
because it was highly correlated to age at first injection.
2.4. Ethical Issues. Data collection was approved by the
French individual data protection authority (CNIL), and
safeguards on confidentiality, anonymity of responses, and
the nonregistration of IP addresses were clearly stated on the
home page of the survey.
3. Results
3.1. Subjects. Among the 1,884 individuals who visited the
PrimInject URL (http://www.shoot-premierefois.com/), 1,318
(70%) began to fill out the questionnaire. Among these
individuals, 325 (25%) stopped completing the questionnaire
before reaching the end of the section on first injection
and were excluded from the analysis and 42 (3%) provided
inconsistent answers. Most of these individuals discontinued
completion or left the webpage at the very beginning of
the questionnaire, in the general information section. The
individuals who dropped out were younger than those who
continued (mean age 27.6 versus 29.7, 𝑝 < 0.01) and were
more often students. Among the 951 respondents, 455 had
never injected (48%), 40 were living abroad (4%), and seven
did not report the year of their first injection. In the present
study, for internal consistency, only the responses of the 262
individuals who reported injecting drugs for the first time in
or after 2000 were analysed (Figure 1).
More than one-third of these respondents (37%) learned
about the study through the Internet (through banners on the
associations’ websites) and 34%were invited to participate by
outreach services (Table 1).
3.2. Sample Characteristics. More than two-thirds of the
respondents (65%) were male and the mean age was 25 years
(SD = 6) (Table 1). Only 29% of the respondents were
employed, whereas 45% were unemployed and 26% were
students. Regarding education, 51% had not completed high
school and 26% had a college or university degree. Regarding
drug use history, 64% reported early alcohol abuse and
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<High school graduation 132 50.8
High school graduation 60 23.1
>High school graduation 68 26.1
Early substance use
Drunkenness at the age of 14 or younger 168 64.1
Only cannabis at the age of 14 or younger 98 38.7
Other illegal drug use at the age of 14 or younger 52 20.6
Age under 18 at first injection 68 26.0
Location
In a private location 179 68.6
At a party 47 17.9
Circumstances
Injection planned (yes) 94 35.9
Injection while being alone 68 26.0
Injected by another person 138 52.7
Drug given (versus bought) 83 31.7
Substance first injected
Heroin 152 58.0
Cocaine, freebase, and crack 39 14.9
Other opiates 39 14.9
Other drugs 32 12.2
Injected in the last 30 days prior to data collection 158 68.4
Lifetime number of injections
One 31 11.8
Two to ten 37 14.1
More than ten 194 74.1
60% early cannabis or other illegal substance use (39%
only cannabis and 21% another drug). At the time of data
collection, 12% reported having injected only once and 14%
having injected only two to ten times in their lifetime. The
majority of the sample (68%) had injected drugs at least once
in the previous month.
Twenty-six percent (26%) of the respondents had expe-
rienced their first injection before the age of 18 years. Most
respondents reported having injected for the first time in a
private place, for example, house, apartment, or hotel (69%),
and 18% during a party, whatever the context and location
(8% reported having injected during a party in a private
place). Initiation was planned by 36% of the sample, and 26%
were alone at the time. A significant proportion of the sample
reported that they had injected themselves (47%). Heroinwas
the drug most commonly injected at first injection (58%),
followed by other opiates (15%) and cocaine and crack or
freebase (15%).
3.3. Univariate Analyses. Among the 262 respondents, 18 did
not remember whether the syringe that they used the first
time had already been used (Table 2). Among the remaining
244 respondents, 8% (𝑛 = 20) reported that they had used
a syringe already used by another person. The respondents
who were female (crude odds ratio (cOR) = 2.6, 𝑝 = 0.040),
under 18 years old at the time of initiation (cOR = 4.5,
𝑝 = 0.002), and injected by another individual (cOR = 3.1,
𝑝 = 0.036) were more likely to report needle sharing than
other participants. The association between needle sharing
and initiation during a party was only marginally significant
(cOR = 2.7, 𝑝 = 0.062).
Among the 230 subjects who recalled the use of a cooker
or cotton filter, 17% (𝑛 = 40) reported receptive sharing of this
equipment. Except for one individual, all of the individuals
who used a shared needle also used a cooker or cotton
previously used by another person. Correlates significantly
associated with sharing equipment were gender (females:
cOR = 2.3, 𝑝 = 0.020), first injection before the age of 18
(cOR = 2.9, 𝑝 = 0.004), first injection during a party (cOR =
3.3, 𝑝 = 0.004), not having planned to inject (cOR = 2.4,
𝑝 = 0.031), having been injected by another person (cOR =
3.7, 𝑝 = 0.001), and having been given the injected substance
(cOR = 2.8, 𝑝 = 0.004).
3.4. Multivariate Analysis. After adjustment, gender was not
significantly associated with syringe or equipment sharing.
Injection before the age of 18 (adjusted odds ratio (aOR) =
3.7, 𝑝 = 0.015) and injection performed by another person
(aOR = 3.1, 𝑝 = 0.049) were positively associated with
receptive syringe sharing (Table 2).
In the multivariate analysis, receptive equipment sharing
was positively associated with injection before 18 years of
age (aOR = 3.0, 𝑝 = 0.011) and injection performed by
another person (aOR= 3.0,𝑝 = 0.010) (Table 2). A borderline
significant association was found with first injection during a
party (aOR = 2.6, 𝑝 = 0.053).
4. Discussion
The final model showed that younger age and being injected
by another IDU were independently associated with
increased risk in both syringe and other equipment at first
injection. A nearly significant association was also found
between injection at a party and equipment sharing.
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Table 2: Correlates of risk behaviours at time of first injection: crude odds ratios (cOR), adjusted odds ratios (aOR), and 95% confidence
intervals (CI).
Receptive syringe sharing (𝑁 = 244) Receptive cooker or cotton sharing (𝑁 = 230)
cOR 95% CI 𝑝 value aOR 95% CI 𝑝 value cOR 95% CI 𝑝 value aOR 95% CI 𝑝 value
Female (ref = male) 2.6∗ [1.0–6.6] 0.040 1.6 [0.6–4.5] 0.387 2.3∗ [1.1–4.6] 0.020 2.0 [0.9–4.4] 0.095
Current injector at time of
data collection (injection in
the last 30 days) (ref = no)
1.7 [0.5–5.3] 0.373 0.8 [0.4–1.6] 0.478
Characteristics and
circumstances of first injection
Period 2000–2005 (ref =
2006–2010) 1.3 [0.5–3.2] 0.617 1.1 [0.5–2.1] 0.852
Injection before the age of 18
(ref = no) 4.5
∗∗ [1.8–11.4] 0.002 3.7∗ [1.3–10.6] 0.015 2.9∗∗ [1.4–5.9] 0.004 3.0∗ [1.3–7.0] 0.011
Injection in a private location
(ref = other places (e.g.,
outdoors and car))
0.5 [0.2–1.4] 0.187 0.7 [0.2–1.9] 0.460 0.6 [0.3–1.2] 0.178 0.9 [0.4–2.1] 0.839
Injection during a party
(whatever the context) (ref =
no)
2.7 [1.0–7.5] 0.062 1.7 [0.5–5.6] 0.404 3.3∗∗ [1.5–7.4] 0.004 2.6 [1.0–6.8] 0.053
Injection not planned (ref =
planned) 1.1 [0.4–2.8] 0.855 0.9 [0.3–2.7] 0.898 2.4
∗ [1.1–5.3] 0.031 2.2 [0.9–5.6] 0.088
Injected by another person
(ref = no) 3.1
∗ [1.1–8.7] 0.036 3.1∗ [1.0–9.9] 0.049 3.7∗∗ [1.7–8.0] 0.001 3.0∗ [1.3–7.1] 0.010
Drug given (ref = bought) 1.3 [0.5–3.5] 0.545 0.9 [0.3–2.7] 0.834 2.8∗∗ [1.4–5.7] 0.004 2.0 [0.9–4.4] 0.088
Drug injected (ref = heroin)
Cocaine, freebase, and
crack 0.8 [0.2–3.1] 0.831 1.0 [0.4–2.7] 0.986
Other opiates 0.8 [0.2–3.1] 1.1 [0.4–2.8]
Other drugs 0.4 [0.0–3.0] 1.2 [0.4–3.6]
𝑝 values of Wald tests for logistic regressions. ∗∗𝑝 < 0.01; ∗𝑝 < 0.05.
To date, most epidemiological studies on the circum-
stances of initiation into drug injection aremainly descriptive
and have been carried out among IDUs whose injection dates
to the period before 2000 [26, 27, 29–31, 35–39]. PrimInject
joins the few studies investigating the independent correlates
of sharing behaviours at the time of first injection [28, 45].
This study is also the first to examine initiation into drug
injection using an Internet survey. Thus, a significant part
of the sample was not recruited through treatment or harm
reduction services, therefore allowing connectionwith young
IDUs who were not necessarily street-entrenched or in need
of services.
Our findings are consistent with the literature showing
that injection equipment (cooker/cotton filter) sharing is
more prevalent than needle sharing [27, 29, 30, 38, 39, 46].
The rate of sharing injection equipment among injectors of
our sample is consistent with recent results from the French
Ena-Caarud study among new injectors [10]. However, the
definition of “equipment” is highly variable across studies and
precludes valuable comparisons.
Despite a decreasing trend in drug injection thanks to
harm reduction policy, injection drug use has remained
relatively common in France, as shown by recent studies [4,
10], suggesting a need to study in more depth routes to entry
into injection. In our study, risky injection behaviours are
strongly associated with being injected by a third person, as
observed in previous studies [27, 29, 47–49]. These practices
might be linked to the important affective and emotional
influences among couples as discussed elsewhere [32, 50, 51].
Because being injected by an experienced injector is very
common (more than half of the first injections required such
external help) and triples the likelihood of sharing needles
and equipment, the influence of experienced users is key
regarding the ability to demonstrate and practise safer use
[34, 52, 53]. Interventions, such as the brief motivational
intervention Break the Cycle [54], are designed to reduce,
among people who inject drugs, injection initiation-related
behaviours (e.g., speaking positively about injecting to non-
injectors, injecting in front of noninjectors, and explaining
or showing a noninjector how to inject) and initiation of
noninjectors.The evaluation of the intervention reported that
after the intervention, the participants were less likely to
initiate drug users into injecting. This intervention has been
recently evaluated with a peer-delivered design to increase
awareness of the role of experienced users as peer educators.
For example, the Toronto intervention Change the Cycle
(CTC) included attitudes not only towards responding to
young users’ demand for injection but also towards teaching
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safer injection practices. Pilot study results suggest that
CTC holds promise as a preventive intervention [55] and is
currently under study in France. Our findings also support
moving more broadly towards educational interventions on
risks associated with drug injection, such as face-to-face
educational sessions on safer injecting practices that have
recently proved successful in France at reducing unsafe HIV-
HCV transmission practices and injection-related complica-
tions [56].
If the unplanned injection and having been given the
injected substance appear to increase the risk of sharing
equipment in the univariate analyses, this association did not
hold after adjustment suggesting a confounding effect. In fact,
an important result of our analysis also indicates that sharing
equipment was more common when injection took place
during parties. The party atmosphere appeared to favour the
loss of control over the situation, the group effect, and diffi-
culty in identifying clean equipment, especially among drug
users without previous injection experience [57]. A range
of harm reduction programmes targeting the party scene
have been launched, such as the Nevershare Syringe, with
plungers in a range of colours to prevent accidental sharing
[58]. In France, more specific harm reduction programmes
targeting the recreational use of drugs in the techno scene
have also included injection and prevention of sharing in
their portfolio (http://www.technoplus.org/). The PrimInject
findings support the renewed development of programmes
targeting youth involved in the party scene, where multiple
illegal substances arewidely available and there is a significant
chance of moving to injection practices.
Additionally, unlike previous results that indicated an
association between cocaine injection and higher drug use
practices [59–62], the PrimInject results found that, at the
first injection, the use of cocaine and other stimulants did
not increase the sharing of either syringes or equipment.
However, early initiation into injection (under the age of 18)
was correlated with needle and equipment sharing at the time
of first injection. Early injection was strongly correlated with
early experience of illegal drug use (𝑝 < 0.001): among the
respondents who injected before the age of 18, 45% had used
an illicit drug other than cannabis at the age of 14 or younger
(versus 12% of the respondents who initiated injection at
the age of 18 or older). Other individual factors were not
documented to assess the various dimensions of vulnerability
associated with the early onset of at-risk behaviours, such
as poor family relationships, family history of alcohol and
drug abuse, childhood trauma, and early school dropout [63–
66]. Initiation into drug use, including injection initiation in
teenage years, puts young people at increased risk of drug-
related harm and calls for an update of harm reduction
services to address their specific needs [67]. These results
reinforce the need for early identification, referral, and
intervention with young people at risk, such as the clinics
for young drug users launched in France in 2004. Within
this framework, a comprehensive programme for preventing
a large range of addictions (e.g., tobacco, alcohol, cannabis,
and video games) includes information and communication
campaign and outpatient clinics adapted to young drug users
and their families [68]. Early interventions, such as Screening,
Brief Intervention, and Referral to Treatment (SBIRT), enable
addressing high-risk drug users more effectively and help
reduce harm associated with drug abuse, particularly among
thosewhodonot seek help [69]. If this public health approach
has proved successful among adults, it must be tailored to the
changing and evolving needs of specific young target groups
and new drug trends [70]. For this purpose and because of
challenges posed by changing consumption patterns among
young people in the fight against infectious diseases, such
as HIV and HCV, there is an urgent need to introduce new
forms of intervention and services based on information and
communication technologies and targeting very young drug
users.
4.1. Strengths and Weaknesses. While prior studies on the
transition to injection were mostly based on samples
recruited in dedicated drug services or using targeted sam-
pling, street outreach, or chain referral methods among
mostly marginalised users [26–29, 31, 35–39], PrimInject
reached a diverse populationwith respect to social status, age,
past and present drug use patterns, frequency of drug use,
and current behaviour and carrier in injection [40].The study
has been restricted to young people (mean age 25 years) who
began injection in recent years (2000–2010) and captures
a little known population that could not yet have had a
long career in injection. The purpose of the study was to
portray the entire spectrum of people who currently inject
drugs, including those individuals with a very short history
of drug injection, who represent a quarter of the sample, with
12% having injected only once and 14% two to ten times in
their lifetime. These drug users are exposed to transmission
of blood-borne infections, mainly HCV, in cases of unsafe
practices.
Recall bias cannot be excluded, especially among those
from the most remote period of initiation. Desirability
bias cannot be ruled out; however, compared with more
conventional modes of data collection, the anonymity of the
web administration could increase the level of reporting of
sensitive information and its accuracy [71, 72].
Conversely, recent injectors are more likely to use the
Internet and to attend social events or services where the
PrimInject information was promoted.This surveymode and
its effort to reach electronic scene users may have biased
the recruitment in favour of the least marginalised injectors.
However, a sizeable proportion (approximately one-third) of
the sample was recruited through outreach teams outside the
Internet channel. Furthermore, the factors associated with
sharing outcomes were not significantly associated with how
participants reached the PrimInject website, either through
outreach programmes or while surfing the Internet on their
own. In such a hard-to-reach population, thePrimInject study
does not claim to be statistically representative; rather, it cov-
ers a spectrum of users broader than that usually investigated
[40]. Given the consistency of the PrimInject findings with
new drug use trends in France, as regards the age of new
initiates to injection and persistence of sharing equipment
practices [40], the PrimInject results might be considered to
reflect current at-risk practices and their determinants that
favour the ongoing transmission of HCV.
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5. Conclusions
The context of new patterns of drug use and emerging
new consumer profiles among young people presents new
challenges for harm reduction among young people. Initia-
tion into drug use persists, and it carries potential risk for
extremely diverse groups. This research identifies risk con-
texts during the first injection and encourages taking them
into account in innovative (outreach, peer, and online) harm
reduction programmes addressed both to people who inject
occasionally during parties and festivals and to those who
willmove towards long-lasting drug use injection trajectories.
In this context, the education of current injectors to protect
both themselves and those they might initiate into injection
is critically important. This diversification of harm reduction
programmes in combination with efforts to improve access to
highly effective HCV treatment could make further progress
in reducing HCV prevalence and incidence.
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